NCT00134433View on ClinicalTrials.gov

Endothelial Modulation for Angiogenic Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

October 31, 2007

Conditions
Coronary Artery Disease
Interventions
GENETIC

intramyocardial VEGF angiogenesis (at a dose of 2 mg)

DRUG

oral L-arginine supplementation (at a dose of 6 g/day)

Trial Locations (1)

K1Y 4W7

Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Ontario

OTHER

lead

Ottawa Heart Institute Research Corporation

OTHER

NCT00134433 - Endothelial Modulation for Angiogenic Therapy | Biotech Hunter | Biotech Hunter